Madhavi Kamireddi, MD
Psychiatry · Acton, MANPI 1255313466
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,920 of the $33,098 with a category attached, or 63.2%. Supernus Pharmaceuticals, Inc. accounts for 69.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $23,104 and has fallen 95.8% since, to $981 in 2024. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $312.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$23K
- Ironshore Pharmaceuticals Inc.$8K
- Johnson & Johnson$906
- Otsuka America Pharmaceutical, Inc.$242
- Sunovion Pharmaceuticals Inc.$109
- Tris Pharma Inc$97
- plus $276 from 8 others
What the payments were for
- Consulting fees$4,00012%
- Speaking & faculty fees$20,92063%
- Travel & lodging$6,18819%
- Food & beverage$1,9906%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 28 | $23,104 |
| Ironshore Pharmaceuticals Inc. | 26 | $8,364 |
| Johnson & Johnson | 11 | $906 |
| Otsuka America Pharmaceutical, Inc. | 12 | $242 |
| Sunovion Pharmaceuticals Inc. | 9 | $109 |
| Tris Pharma Inc | 6 | $97 |
| Neurocrine Biosciences, Inc. | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Lundbeck LLC | 2 | $43 |
| Shire North American Group Inc | 2 | $43 |
| Neuronetics, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$19,910
- Jornay PM 20mg capsules (Bottle of 100)$7,677
- SPRAVATO$573
How this compares
$33,098 in reported general payments places this provider in the 95th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FetzimaLevomilnacipran Hcl | 11 | $5,427 |
| Bupropion XlBupropion Hcl | 23 | $576 |
| Trazodone Hcl | 17 | $361 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $236 |
| Citalopram HbrCitalopram Hydrobromide | 21 | $123 |
| Lamotrigine | 18 | $44 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Acton
- Brian AckermanActon$13K
- Theresa CerulliNorth Andover$724K
- Andrew AldridgeMedford$407K
- Amjad BahnassiWorcester$352K
- Ximena Sanchez-SamperBoston$258K
- Robert AlexanderBelmont$170K
- George PapakostasBoston$170K
- Xiangyang LiMilford$166K
- Ernesto ZilberbergNorth Andover$141K
- Maurizio FavaBoston$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.